Navigation Links
Alexza's AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
Date:3/3/2008

Initial Analysis Shows Statistically Significant Pain Relief with the 2.5

and 5 mg Doses Compared to Placebo

MOUNTAIN VIEW, Calif., March 3 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today positive top-line results from its 168 patient Phase 2a clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache. Migraine is a debilitating, yet common neurological disorder characterized by attacks of severe headache and autonomic nervous system dysfunction. Two doses of AZ-104, 2.5 and 5 mg, met the primary endpoint of 2-hour pain-relief compared to placebo. Alexza believes the novel, non-invasive nature and rapid pharmacokinetic (PK) properties resulting from inhaled loxapine administration via the Staccato system have the potential to make AZ-104 a viable product to treat acute migraines. AZ-104 is a lower dose version of AZ-004, which is in Phase 3 clinical development for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. AZ-004 and AZ-104 are being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.

"Loxapine is a potent antagonist at dopamine D2 receptors as well as serotonergic 5-HT2A receptors. While drugs that antagonize the D2 receptor are efficacious in treating migraine, it was proposed that the 5HT2A receptor antagonism might yield an improved adverse effect profile over drugs blocking primarily the D2 receptor. This dual mechanism of pharmacological action provided the scientific rationale to study AZ-104 in this proof-of-concept clinical trial," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza and chairman
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
9. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
10. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DRRX ) announced today financial results for the second ... loss was $5.5 million for the three months ended June ... and net loss of $5.5 million for the three months ... and investments of $37.8 million, compared to cash and investments ... 2015, we had $19.8 million in long term debt. ...
(Date:8/3/2015)... PARSIPPANY, N.J. , Aug. 3, 2015  LEO ... and Drug Administration (FDA) to include psoriasis as one ... Focused Drug Development Initiative i .  Psoriasis is an ... lives and subsequent comorbidities, affecting 7.5 million people in ... of LEO Pharma,s ongoing commitment to supporting patients living ...
(Date:8/3/2015)... N.Y. , Aug. 3, 2015 ... Wilmot Cancer Institute to the OmniSeq SM ... Roswell Park Cancer Institute (RPCI) and announced it ... that support a physician-driven, collaborative approach to genomic ... outcomes.  Wilmot Cancer Institute is a rapidly expanding, ...
Breaking Medicine Technology:DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 9DURECT Corporation Announces Second Quarter 2015 Financial Results and Update of Programs 10LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 2LEO Pharma Supports the FDA's Selection of Psoriasis as a Priority Disease 3OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... Researchers at Brigham and Women,s,Hospital found that patients taking ... effects were unrelated to relief from their pain,symptoms. ... examine the addictive,potential of this class of pain medicine, ... 25th Annual Meeting. , In ...
... Lethal ,Super, Strains of C.difficileCHICAGO, Jan. 28 ... scientists at The University of Nottingham are leading a ... one of the most lethal strains of hospital acquired ... technology developed in Nottingham to study the function of ...
Cached Medicine Technology:Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 2British Midlands University Announces Use of Gene Technology to Fight Lethal Hospital Acquired Infection 3
(Date:8/4/2015)... ... August 04, 2015 , ... ... other long-term care facilities, today announced details of the Advanced level of their ... centers. , Providigm’s QAPI Accreditation program , introduced in 2013, is based ...
(Date:8/4/2015)... Vegas, Nevada (PRWEB) , ... August 04, 2015 ... ... FEMALE, a striking contemporary look at unique artistic expressions from a diverse group ... inside the Life Is Beautiful Music & Art Festival on September 25-27, 2015 ...
(Date:8/4/2015)... D.C. (PRWEB) , ... August ... ... that its HealthCenter personal health record (PHR) product has achieved Office of ... and Inpatient EHR Certification from Drummond Group. HealthCenter delivers the highest quality ...
(Date:8/4/2015)... ... August 04, 2015 , ... Driving skills may ... to driving, says the August 2015 Harvard Health Letter. , "Age and health ... requires an individual assessment of skills," says Lissa Kapust, a social worker at ...
(Date:8/4/2015)... ... August 04, 2015 , ... METTLER TOLEDO has announced ... featuring researchers from Lubrizol, Pfizer, and Merck. This free online seminar will ... project timelines often require informed decisions with limited process understanding. Established methods ...
Breaking Medicine News(10 mins):Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 2Health News:MedicaSoft's HealthCenter Earns ONC-HIT Certification from Drummond Group 3Health News:Assessment Can Help Older Drivers Keep Driving Safely, from the August 2015 Harvard Health Letter 2Health News:METTLER TOLEDO Announces New Process Chemistry and Scale-up Online Seminar 2
... ... conducted by the US Department of Health and Human Services. , ... Austin, TX (PRWEB) September 25, 2009 -- RCRC Independent ... will provide oversight of research supported or conducted by a federal department or agency within ...
... and weight are shaped by their social class, according to ... Policymakers have long insisted on the importance of ... the first study to show how everyday practices and perceptions ... weight and health of teenagers. ,It is evident that ...
... says it will review procedure for endorsing medical devices ... Food and Drug Administration violated procedures last year when ... own scientists recommended against approval, agency officials said Thursday. ... Jersey-based ReGen Biologics and is used to help surgically ...
... SAN FRANCISCO, CA SEPTEMER 24, 2009 Results ... that the combination of giving patients clopidogrel, a blood ... stomach medicines such as omeprazole, known as proton pump ... some prior studies had suggested. The results were presented ...
... , , NEW YORK, Sept. ... Ashoka will partner to create the first international fellowship program ... improve maternal health in developing countries. The Maternal Health Task ... Maternal Health Program as a commitment to action at the ...
... , , , ... Health Registry is expanding its service area across Oklahoma by partnering ... Web service on November 1st, 2009. , , ... has nearly doubled from 1.3 million people served by the Emergency ...
Cached Medicine News:Health News:RCRC Independent Review Board Announces DHHS Research Oversight 2Health News:Social background weighs heavily on teenage diet 2Health News:FDA Acknowledges Mistakes in Knee-Device Approval 2Health News:Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine 2Health News:Building the Next Generation of Global Leaders - Maternal Health Task Force and Ashoka Partner 2Health News:Building the Next Generation of Global Leaders - Maternal Health Task Force and Ashoka Partner 3Health News:Oklahoma Medics Embracing iB Web Service 2
... FDA-cleared third-generation allergy test , 3gAllergy is ... It provides quantitative determination of allergen-specific IgE ... accuracy and lot-to-lot reproducibility. The assay delivers ... help you identify, monitor and manage patients ...
The 6.5mm cannulated cancellous ACE SCFE Screw is specifically designed for the treatment of slipped capital femoral epiphysis. The ACE SCFE Screw simplifies insertion and facilitates removal....
Smith & Nephew offers a wide variety of cannulated screw products. Most screw sizes are available in both partially threaded and fully threaded versions. , ,All systems optimize implant strength with...
... Retrograde Humeral Nail enables fixation of humeral ... that may be associated with antegrade nailing. ... and distal interlocking using a nail-mounted targeting ... interlocking with the patient in the prone ...
Medicine Products: